Xenobiotic tracers uncover the gastrointestinal passage, cellular uptake and Ago2 loading of milk microRNAs in neonates

Abstract

Background and aims Exclusive breastfeeding is the best source of nutrition for most infants, but it is not always possible. Enteral nutrition influences intestinal gene regulation and the susceptibility for inflammatory bowel disorders, such as necrotizing enterocolitis (NEC). In modern neonatology it is observed that lactase activity increases during intestinal maturation, but formula-fed infants exhibit lower activity levels than milk-fed infants. Since human breast milk has a high miRNA content in comparison to other body fluids, it is controversially discussed whether they could influence gene regulation in term and preterm neonates and thus might vertically transmit developmental relevant signals.

Methods Following their cross-species profiling via miRNA deep-sequencing we utilized dietary xenobiotic taxon-specific milk miRNA as tracers in human and porcine neonates, followed by functional studies in primary human fetal intestinal epithelial cells (HIEC-6) using Ad5-mediated miRNA-gene transfer.

Results Mammals have in common a large number of milk miRNAs yet exhibit taxon-specific miRNA fingerprints. We traced intact bovine-specific miRNAs from formula-nutrition in human preterm stool and 9 days after the onset of enteral feeding in intestinal cells of preterm piglets. Few hours after introducing enteral feeding in preterm piglets with supplemented reporter miRNAs (cel-miR-39-5p/-3p), we observed enrichment of the xenobiotic cel-miR in blood serum and in Ago2-immunocomplexes from intestinal biopsies. This points to a transmissibility of milk miRNA signals. We performed Adenovirus type 5-based miRNA-gene transfer into HIEC-6 and examined predicted bovine milk miRNA targets on the protein and transcriptome levels.

Conclusions Results suggest that milk miRNAs could influence gene expression in intestinal epithelia of neonates under special conditions in vitro.

Synopsis We provide a line of evidence that vertical transmission of milk miRNA signals via GI transit towards responsive cells and systemic bloodstream distribution is possible. This will prompt the understanding about milk miRNA bioactivity with respect to neonatal intestinal maturation.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Not relevant

Funding Statement

This study was funded by the HELIOS Research Centre (JP) and the NEOMUNE research program (PTS) from the Danish Research Councils. University of Copenhagen has filed a patent concerning the use of bovine colostrum for groups of paediatric patients. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilised in the production of this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval and consent to participate This study was conducted with approval of the Witten/Herdecke University Ethics board (No. 41/2018). All animal procedures were approved by the National Council on Animal Experimentation in Denmark (protocol number 2012-15-293400193). The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from all participants.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes